Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia
MJ Fell, DL McKinzie, JA Monn, KA Svensson - Neuropharmacology, 2012 - Elsevier
Schizophrenia is a devastating chronic psychotic disorder characterized by positive,
negative, and cognitive symptoms. Although the positive symptoms are relatively well …
negative, and cognitive symptoms. Although the positive symptoms are relatively well …
Group II metabotropic glutamate receptors as targets for novel antipsychotic drugs
Schizophrenia is a chronic psychiatric disorder which substantially impairs patients' quality
of life. Despite the extensive research in this field, the pathophysiology and etiology of …
of life. Despite the extensive research in this field, the pathophysiology and etiology of …
CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [3H] LY459477 autoradiography
RA Wright, BG Johnson, C Zhang, C Salhoff… - …, 2013 - Elsevier
Group II metabotropic glutamate (mGlu) receptor agonists were efficacious in randomized
clinical research trials for schizophrenia and generalized anxiety disorder. The regional …
clinical research trials for schizophrenia and generalized anxiety disorder. The regional …
Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: Modulation of glutamate release reverses dopamine depletion–induced …
BG Garcia, MD Neely, AY Deutch - Cerebral Cortex, 2010 - academic.oup.com
Striatal medium spiny neurons (MSNs) receive glutamatergic afferents from the cerebral
cortex and dopaminergic inputs from the substantia nigra (SN). Striatal dopamine loss …
cortex and dopaminergic inputs from the substantia nigra (SN). Striatal dopamine loss …
Glutamate and dopamine components in schizophrenia
P Seeman - Journal of Psychiatry and Neuroscience, 2009 - jpn.ca
The treatment of schizophrenia for the last half century has been with dopamine (DA) D 2
receptor blockers, implicating a hyperdopamine basis for psychosis. However, a 2007 report …
receptor blockers, implicating a hyperdopamine basis for psychosis. However, a 2007 report …
The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat
Rationale Current antipsychotics are ineffective at treating the negative and cognitive
symptoms of schizophrenia, so there is a substantial need to develop more effective …
symptoms of schizophrenia, so there is a substantial need to develop more effective …
Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?
ML Li, XQ Hu, F Li, WJ Gao - Progress in Neuro-Psychopharmacology and …, 2015 - Elsevier
Group II metabotropic glutamate receptor (mGluR2/3) agonists once showed promise as non-
dopaminergic antipsychotic drugs because of their efficacy in alleviating symptoms of …
dopaminergic antipsychotic drugs because of their efficacy in alleviating symptoms of …
Historical overview: introduction to the dopamine receptors
P Seeman - The dopamine receptors, 2010 - Springer
A long-term search for the mechanism of action of antipsychotic drugs was motivated by a
search for the cause of schizophrenia. The research between 1963 and 1975 led to the …
search for the cause of schizophrenia. The research between 1963 and 1975 led to the …
Role of metabotropic glutamate receptors in the control of neuroendocrine function
Glutamate exerts its effects through binding and activation of two classes of specific
receptors: ionotropic (iGluRs) and metabotropic (mGluRs). Group I mGluR includes mGluR1 …
receptors: ionotropic (iGluRs) and metabotropic (mGluRs). Group I mGluR includes mGluR1 …
Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion
AL Pehrson, B Moghaddam - Psychopharmacology, 2010 - Springer
Rationale Activation of metabotropic glutamate (mGlu) 2/3 receptors may provide a novel
strategy for treating schizophrenia. This effect is thought to be mediated through dopamine …
strategy for treating schizophrenia. This effect is thought to be mediated through dopamine …